Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR project
{{output}}
Background: Circulating tumor DNA (ctDNA) dynamics have emerged as a promising biomarker of treatment response in oncology drug development. Early decreases in ctDNA levels after treatment initiation are associated with improved ... ...
